Neurocrine Biosciences (Neurocrine Biosciences) COGS-to-Revenue : 0.02 (As of Dec. 2023)

View and export this data going back to 1996. Start your Free Trial

What is Neurocrine Biosciences COGS-to-Revenue?

Neurocrine Biosciences's Cost of Goods Sold for the three months ended in Dec. 2023 was $9 Mil. Its Revenue for the three months ended in Dec. 2023 was $515 Mil.

Neurocrine Biosciences's COGS to Revenue for the three months ended in Dec. 2023 was 0.02.

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin. Neurocrine Biosciences's Gross Margin % for the three months ended in Dec. 2023 was 98.35%.

Neurocrine Biosciences COGS-to-Revenue Historical Data

The historical data trend for Neurocrine Biosciences's COGS-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Neurocrine Biosciences COGS-to-Revenue Chart

Neurocrine Biosciences Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

COGS-to-Revenue

Get a 7-Day Free Trial

0.01

0.02

Neurocrine Biosciences Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
COGS-to-Revenue	Get a 7-Day Free Trial															0.02	0.02	0.03	0.02	0.02

Neurocrine Biosciences COGS-to-Revenue Calculation

Neurocrine Biosciences's COGS to Revenue for the fiscal year that ended in Dec. 2023 is calculated as

COGS to Revenue	=	Cost of Goods Sold	/	Revenue
	=	39.7	/	1887.1
	=	0.02

Neurocrine Biosciences's COGS to Revenue for the quarter that ended in Dec. 2023 is calculated as

COGS to Revenue	=	Cost of Goods Sold	/	Revenue
	=	8.5000000000001	/	515.2
	=	0.02

Neurocrine Biosciences (NAS:NBIX) COGS-to-Revenue Explanation

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin.

Neurocrine Biosciences's Gross Margin % for the three months ended in Dec. 2023 is calculated as:

Gross Margin %	=	1	-	COGS to Revenue
	=	1	-	Cost of Goods Sold / Revenue
	=	1	-	8.5000000000001 / 515.2
	=	98.35 %

A company that has a moat can usually maintain or even expand their Gross Margin. A company can increase its Gross Margin in two ways. It can increase the prices of the goods it sells and keeps its Cost of Goods Sold unchanged. Or it can keep the sales price unchanged and squeeze its suppliers to reduce the Cost of Goods Sold. Warren Buffett believes businesses with the power to raise prices have moats.

Neurocrine Biosciences COGS-to-Revenue Related Terms

Thank you for viewing the detailed overview of Neurocrine Biosciences's COGS-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Neurocrine Biosciences (Neurocrine Biosciences) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Neurocrine Biosciences Inc (NAS:NBIX) » Definitions » COGS-to-Revenue

Comparable Companies

Traded in Other Exchanges

NB3:Germany NB3:Germany N1BI34:Brazil

Address

12780 El Camino Real, San Diego, CA, USA, 92130

Website

https://www.neurocrine.com

Neurocrine Biosciences Inc is a research-based pharmaceutical company advancing drug candidates in the central nervous system and endocrine-related categories. The company's three late stage clinical programs are elagolix which is hormone releasing antagonist for women's health, opicapone which is an inhibitor for parkinson's patients, and ingrezza for tourette syndrome.

Executives

Kevin Charles Gorman	officer: Sr VP, Business Development	12790 EL CAMINO REAL, SAN DIEGO CA 92130
William H Rastetter	director	9885 TOWNE CENTRE DR., SAN DIEGO CA 92121
Kyle Gano	officer: Chief Business Dev Officer	NEUROCRINE BIOSCIENCES, INC., 12780 EL CAMINO REAL, SAN DIEGO CA 92130
Eiry Roberts	officer: Chief Medical Officer	C/O NEUROCRINE BIOSCIENCES, INC., 12780 EL CAMINO REAL, SAN DIEO CA 92130
Julie Cooke	officer: Chief Human Resources Officer	C/O NEUROCRINE BIOSCIENCES, INC., 12780 EL CAMINO REAL, SAN DIEGO CA 92130
Gary A Lyons	director, officer: President and CEO	12790 EL CAMINO REAL, C/O NEUROCRINE BIOSCIENCES, SAN DIEGO CA 92130
Darin Lippoldt	officer: Chief Legal Officer	C/O VOLCANO CORPORATION, 3661 VALLEY CENTRE DRIVE, SUITE 200, SAN DIEGO CA 92130
Jude Onyia	officer: Chief Scientific Officer	C/O NEUROCRINE BIOSCIENCES, INC., 12780 EL CAMINO REAL, SAN DIEGO CA 92130
David W. Boyer	officer: Chief Corp. Affairs Officer	C/O NEUROCRINE BIOSCIENCES, INC., 12780 EL CAMINO REAL, SAN DIEGO CA 92130
Ingrid Delaet	officer: Chief Regulatory Officer	C/O NEUROCRINE BIOSCIENCES, INC., 12780 EL CAMINO REAL, SAN DIEGO CA 92130
Matt Abernethy	officer: Chief Financial Officer	C/O NEUROCRINE BIOSCIENCES, INC., 12780 EL CAMINO REAL, SAN DIEGO CA 92121
Eric Benevich	officer: Chief Commerical Officer	C/O NEUROCRINE BIOSCIENCES, INC., 12790 EL CAMINO REAL, SAN DIEGO CA 92130
Christine A Poon	director	C/O JOHNSON & JOHNSON, ONE JOHNSON PLAZA, NEW BRUNSWICK NJ 08933
Malcolm Lloyd-smith	officer: Chief Regulatory Officer	12481 HIGH BLUFF DRIVE, SUITE 200, SAN DIEGO CA 92130
Stephen A Sherwin	director	C/O CELL GENESYS, INC., 500 FORBES BLVD., SOUTH SAN FRANCISCO CA 94080